Klotho Neurosciences

Greenland Mines Ltd. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Charlotte, North Carolina and currently employs 2 full-time employees. The company went IPO on 2022-04-29. The firm is focused is focused on the exploration and development of the Skaergaard Project. The company operates with two operating divisions Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The company operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The firm holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease).